Dupixent® (dupilumab) approved in Egypt for adults and adolescents 12 years and older with moderate-to-severe Atopic Dermatitis & severe Asthma by the Egyptian Drug Authority
Egypt is the 1st country in Africa approved Dupixent for moderate -to - severe Atopic Dermatitis & severe Asthma
Press Release - 20-Apr-2021